Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. UCLH initiates new trial for Alzheimer’s treatment in UK
  2. Brazilian court strips Gilead of its patent for Hepatitis C drug Sovaldi
  3. Hereditary Alzheimer’s: could rare genes hold the key to a cure?
  4. NHS wins landmark ruling against pharma companies over AMD drug
  5. Blood Cancer Awareness Month: revolutionary treatments in the pipeline

Latest Content

Trial design should give Dermira’s AD drug a better shot at Phase IIb success

Dermira’s lebrikizumab Phase IIb trial for atopic dermatitis (AD) has a better shot at statistical and clinical significance with the exclusion of corticosteroid, a class of steroid hormone, use. The outcome should be able to beat efficacy results of Roche’s previous proof-of-concept (POC) trial that tested lebrikizumab with corticosteroids and only achieved a 20% difference versus placebo, the inactive drug or treatment used in a clinical trial.

Roche makes a cautious investment in Ionis’ dAMD drug

Following up on Roche’s first partnership with Ionis Pharmaceuticals for an early-stage pipeline asset for Huntington’s disease, the two companies have signed a second deal, this time focusing on IONIS-FB-LRx, an antisense pipeline drug using Ionis’ advanced Ligand Conjugated Antisense (LICA) technology, which reduces the production of Factor B, a key protein in the complement innate immune system in a broad range of diseases.

ESMO 2018: previewing high-impact, late-breaking abstracts

The 2018 European Society for Medical Oncology (ESMO) Annual Congress will begin in Munich on October 19, where combination therapies and immuno-oncology strategies feature heavily in the highest impact clinical research abstracts. The best studies at the congress, those considered cutting-edge or practice-changing, will be presented during the three plenary sessions, called Presidential Symposia at ESMO.

Data Integrity: A Closer Look

Data integrity continues to be a hot topic impacting the pharma/biotech industry, and the trend has been growing since 2010.

Almirall brings new drug to stagnant US acne market

On October 2, the FDA approved Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older. Seysara was originally developed by Paratek Pharmaceuticals.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top